Belite Bio Future Growth
Future criteria checks 2/6
Belite Bio is forecast to grow earnings and revenue by 58.3% and 59.8% per annum respectively while EPS is expected to grow by 58% per annum.
Key information
58.3%
Earnings growth rate
58.0%
EPS growth rate
| Pharmaceuticals earnings growth | 23.4% |
| Revenue growth rate | 59.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20
An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 34 | -17 | -25 | N/A | 3 |
| 12/31/2025 | 6 | -26 | -32 | -22 | 4 |
| 12/31/2024 | 10 | -23 | -37 | -26 | 5 |
| 12/31/2023 | N/A | -32 | -30 | -30 | N/A |
| 9/30/2023 | N/A | -31 | N/A | N/A | N/A |
| 6/30/2023 | N/A | -23 | N/A | N/A | N/A |
| 3/31/2023 | N/A | -18 | N/A | N/A | N/A |
| 12/31/2022 | N/A | -13 | -12 | -11 | N/A |
| 9/30/2022 | N/A | -8 | N/A | N/A | N/A |
| 6/30/2022 | N/A | -8 | N/A | N/A | N/A |
| 3/31/2022 | N/A | -8 | N/A | N/A | N/A |
| 12/31/2021 | N/A | -10 | -8 | -7 | N/A |
| 9/30/2021 | N/A | -9 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -8 | -7 | -7 | N/A |
| 3/31/2021 | N/A | -7 | -6 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLTE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLTE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLTE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLTE's revenue (59.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: BLTE's revenue (59.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLTE's Return on Equity is forecast to be high in 3 years time